ASCO Secures Major Funding and Data License Agreements for CancerLinQ™


Get Permission

ASCO has secured $3 million in new funding and key data sharing arrangements to support the development of CancerLinQ™, a ground-breaking information technology initiative that aims to achieve higher quality, higher value cancer care with better outcomes for patients.

ASCO’s Conquer Cancer Foundation has received generous commitments from Susan G. Komen for the Cure, Helsinn Group, and Genentech. The Komen gift will support the completion and evaluation of a breast cancer-specific prototype of the CancerLinQ system, while the other two gifts will enable ASCO to begin developing the full system based on lessons learned from the prototype. The new commitments are in addition to roughly $1 million in donor funding already received, as well as ASCO’s own significant investment in the initiative.

ASCO has also completed agreements with Maine Center for Cancer Medicine, Marin Specialty Care and Marin General Hospital, Space Coast Cancer Center and Tennessee Oncology, as well as IntrinsiQ, LLC, to provide anonymous case data on approximately 100,000 patients for inclusion in the CancerLinQ prototype—far more than the target of 30,000 that ASCO had set for this initial stage of development. This comprehensive set of de-identified clinical information on individuals with breast cancer has enabled ASCO to quickly begin assessing the prototype with a robust, real-world dataset.

CancerLinQ™ is supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology. For more information, please visit: www.asco.org/cancerlinq ■

© 2013. American Society of Clinical Oncology. All rights reserved.



Advertisement

Advertisement



Advertisement